Serum sclerostin and glucose homeostasis: No association in healthy men. Cross-sectional and prospective data from the EGIR-RISC study

Sclerostin, an inhibitor of bone formation, has emerged as a potential negative regulator glucose homeostasis. We aimed to investigate if serum sclerostin associates with insulin sensitivity, beta cell function, prediabetes or metabolic syndrome in healthy men. Serum was measured basal and insulin-stimulated samples from 526 men without diabetes the RISC cohort study. An OGTT performed at baseline after 3 years. IVGTT hyperinsulinaemic-euglycaemic clamp were baseline. Insulin sensitivity estimated by oral index (OGIS) M-value relative levels. Beta function assessed acute total secretion (ISRtot) sensitivity. levels correlated positively age but similar individuals (n = 69) 457) syndrome. associated measures neither nor age-adjusted analyses including all participants. However, inversely OGIS follow-up (B: −0.29 (−0.57, −0.01) p 0.045), −13.3 (−26.3, −0.2) 0.046). Associations between 3-year changes homeostasis not observed. Acute hyperinsulinemia suppressed (p 0.02), this reduction ISRtot. Overall, prediabetes, The inverse relationship weak likely clinical relevance. ability reduce sclerostin, possibly promoting needs be clarified.